Treatment of cancer

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).

CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Clinical medicine, CancerVax, Branches of biology, Immunotherapy, Sarcoma, Cancer, Treatment of cancer, Active immunotherapy, Antoni Ribas

The program will focus on developing effective immunotherapies such as CAR T-cell and custom antibodies for Ewing sarcoma.

Key Points: 
  • The program will focus on developing effective immunotherapies such as CAR T-cell and custom antibodies for Ewing sarcoma.
  • This program expands on the preliminary laboratory work done at UCLA by leveraging outside commercial-grade immunotherapy development processes and services.
  • CancerVAX, Inc. is developing immunotherapy cancer treatments that use the bodys immune system to fight cancer.
  • Our research is performed at the UCLA Jonsson Comprehensive Cancer Center by a leading cancer research team.

Worldwide Oncology/Cancer Drugs Industry to 2027 - Increase in Number of Pipeline Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Pharmaceutical, Health, Oncology, Health sciences, Clinical medicine, Medicine, Antineoplastic drugs, Oncology, Cancer treatments, Targeted therapy, Hormonal therapy, Chemotherapy, Treatment of cancer, Cancer, Therapy

The global oncology drugs market was valued at $128,352 million in 2019, and is projected to reach $222,380 million by 2027, registering a CAGR of 7.4%.

Key Points: 
  • The global oncology drugs market was valued at $128,352 million in 2019, and is projected to reach $222,380 million by 2027, registering a CAGR of 7.4%.
  • The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.
  • Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.
  • Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

Retrieved on: 
Friday, May 21, 2021
Life sciences, Health sciences, Branches of biology, Biotechnology, Cell biology, Stem cells, Chimeric antigen receptor T cell, Leukemia, Cell therapy, Therapy, Treatment of cancer, Biopharmaceutical

b'SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\xe2\x80\x9cGracell\xe2\x80\x9d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in relapsed/refractory multiple myeloma.

Key Points: 
  • b'SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\xe2\x80\x9cGracell\xe2\x80\x9d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in relapsed/refractory multiple myeloma.
  • This data was accepted as poster presentation at the 2021 American Society of Clinical Oncology Annual Meeting.\nConference call and webcast details:\nA replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.\nGracell Biotechnologies Inc.\xc2\xa0("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.
  • Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
  • For more information on Gracell, please visit www.gracellbio.com\n'

Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

Retrieved on: 
Thursday, May 20, 2021
Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, Medical physics, Oncology, Gastrointestinal cancer, Pancreatic cancer, Treatment of cancer, Radiation therapy, Chemotherapy

The global pancreatic cancer treatment marketis expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc.

Key Points: 
  • The global pancreatic cancer treatment marketis expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc.
  • Many treatments for pancreatic cancer are available in the market such as chemotherapy, surgery, radiotherapy, and targeted therapy.
  • Whereas the surgery is considered as a first treatment option for pancreatic cancer, just like any other cancer.
  • Pancreatic cancer is one of the painful cancers, and the survivor gets relief only if they get treatment on early stage.

Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

Retrieved on: 
Thursday, May 20, 2021
Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, Medical physics, Oncology, Gastrointestinal cancer, Pancreatic cancer, Treatment of cancer, Radiation therapy, Chemotherapy

The global pancreatic cancer treatment marketis expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc.

Key Points: 
  • The global pancreatic cancer treatment marketis expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc.
  • Many treatments for pancreatic cancer are available in the market such as chemotherapy, surgery, radiotherapy, and targeted therapy.
  • Whereas the surgery is considered as a first treatment option for pancreatic cancer, just like any other cancer.
  • Pancreatic cancer is one of the painful cancers, and the survivor gets relief only if they get treatment on early stage.

Global Epigenetics Market (2020 to 2028) - Size, Share & Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Genetics, Cancer, Epigenetics, Treatment of cancer

b'The "Epigenetics Market Size, Share & Analysis By Product, By Technology, By Application, By End-Use, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nPrevalence of various types of cancer, coupled with rising need for advanced cancer treatment and drugs are key factors driving market revenue growth.\nMarket Size - USD 9,143.1 Million in 2020, Market Growth - CAGR of 18.8%, Market Trends - Increasing research and development to explore novel treatment for cancer.\nThe global epigenetic market size is expected to reach USD 36.52 Billion in 2028, and register a CAGR of 18.8% during the forecast period.

Key Points: 
  • b'The "Epigenetics Market Size, Share & Analysis By Product, By Technology, By Application, By End-Use, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nPrevalence of various types of cancer, coupled with rising need for advanced cancer treatment and drugs are key factors driving market revenue growth.\nMarket Size - USD 9,143.1 Million in 2020, Market Growth - CAGR of 18.8%, Market Trends - Increasing research and development to explore novel treatment for cancer.\nThe global epigenetic market size is expected to reach USD 36.52 Billion in 2028, and register a CAGR of 18.8% during the forecast period.
  • Rising number of deaths by cancer, global geriatric population globally, and rising awareness regarding need for epigenetic are factors expected to drive market growth.
  • According to a report by World Health Organization, number of cancer patients is going to increase to 19.3 Million by 2025 globally.\nHigh cost of instruments required for epigenetics research and maintenance are factors that could hamper market growth to some extent.\n'

Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors

Retrieved on: 
Tuesday, May 18, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Radiobiology, TLR7, Radiation therapy, Treatment of cancer, Physical sciences, Natural sciences, Physics, Seven and Eight Biopharma, Institut Bergonié, SEVEN AND EIGHT BIOPHARMA, INSTITUT BERGONIé

Institut Bergoni\xc3\xa9 is the sponsor of the AGADIR Phase II protocol, \xe2\x80\x9cAtezolizumab combined with BDB001 and Immunogenic Radiotherapy in patients with advanced solid tumors\xe2\x80\x9d ( NCT03915678 ), which will enroll patients with difficult-to-treat solid tumors across 10 clinical centers in France.

Key Points: 
  • Institut Bergoni\xc3\xa9 is the sponsor of the AGADIR Phase II protocol, \xe2\x80\x9cAtezolizumab combined with BDB001 and Immunogenic Radiotherapy in patients with advanced solid tumors\xe2\x80\x9d ( NCT03915678 ), which will enroll patients with difficult-to-treat solid tumors across 10 clinical centers in France.
  • BDB001 is a first-in-class Toll-like receptor 7/8 (TLR7/8) agonist, which is delivered intravenously, allowing for broader treatment of solid tumors compared to intratumoral TLR agonists in development.\n\xe2\x80\x9cWe are delighted to begin this clinical study with BDB001.
  • We offer dedicated inpatient and outpatient cancer treatment including radiotherapy and hemotherapy as well as a number of related support services.
  • As a non-profit private hospital dedicated to public service, we have a three-fold mission: patient care, research and oncology education.

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

Retrieved on: 
Friday, May 14, 2021
Oncology, Health, General Health, Radiology, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Medical specialties, Cancer, Biopsy, Thyroid cancer, Prostate cancer, Treatment of cancer

(Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.

Key Points: 
  • (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.
  • The test uses targeted DNA and whole-transcriptome RNA sequencing to detect alterations in more than 50 genes known to be present in lung cancer.
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • Examples of forward-looking statements include, among others, statements regarding the ability of the Percepta Genomic Atlas to accurately detect known lung-cancer gene variants and help to guide treatment with targeted therapies.

BostonGene Announces Cancer Research Collaboration with the Abramson Cancer Center of the University of Pennsylvania

Retrieved on: 
Tuesday, May 11, 2021
Technology, Hospitals, Genetics, Software, Biotechnology, Managed care, University, Health, Education, Oncology, Cancer vaccine, Vaccination, Oncology, Treatment of cancer, Branches of biology, Medical specialties, Medicine

b"BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.\nThe first research project to arise from this collaboration aims to support clinical research focusing on personalized cancer vaccines, a new approach of active immunotherapy which utilizes the patient\xe2\x80\x99s own immune system to identify tumor specific neoantigens.

Key Points: 
  • b"BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.\nThe first research project to arise from this collaboration aims to support clinical research focusing on personalized cancer vaccines, a new approach of active immunotherapy which utilizes the patient\xe2\x80\x99s own immune system to identify tumor specific neoantigens.
  • BostonGene\xe2\x80\x99s advanced computational algorithms will identify cancer specific neoantigens and profile the immune activation status of the tumor by performing advanced multi-omics analysis, including the interpretation and visualization of cancer patient's genomic, transcriptomic and imaging datasets.
  • \xe2\x80\x9cWe are pleased to support the Abramson Cancer Center by providing sophisticated analytics and integration of scientific and clinical knowledge in an effort to improve the standard of care and redefine the treatment selection approach for cancer patients.\xe2\x80\x9d\nThe ACC, a global leader in basic, translational, clinical, and biomedical research for the advancement of cancer care, is a matrix cancer center embedded within the University of Pennsylvania and the University of Pennsylvania Health System.
  • BostonGene\xe2\x80\x99s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies.